In Brief: FDA's Psychopharmacologic Drugs Advisory Committee
Executive Summary
FDA's Psychopharmacologic Drugs Advisory Committee: Will meet Feb. 6 to discuss Abbott Lab's NDA (20-320) for Depakote (divalproex sodium) tablets for "use in the treatment of manic episodes associated with bipolar disorder." The meeting will begin at 8:30 a.m. in Conference Rooms D and E of FDA's Parklawn Building, Rockville, Md...